Based on surrogate markers of benefit, single-arm studies projected that lung cancer screening with computed tomography (CT) would reduce lung cancer mortality by 80%.1 Yet subsequent randomized clinical trials produced findings ranging from no reduction to a 20% reduction.2 We formally evaluated the seemingly misleading surrogates.
Woo KM, Gönen M, Schnorr G, Silvestri GA, Bach PB. Surrogate Markers and the Association of Low-Dose CT Lung Cancer Screening With Mortality. JAMA Oncol. 2018;4(7):1006–1008. doi:10.1001/jamaoncol.2018.1263
Customize your JAMA Network experience by selecting one or more topics from the list below.